Amgen co-founder William K. Bowes Jr. stands watch over the Thousand Oaks campus. Biosimilars are a double-edged sword for Amgen. Never has that been clearer than when the Thousand Oaks-based biotech giant released fourth quarter and 2015 year-end results on Jan. 28. Despite modest fourth-quarter earnings, investors should not worry. Amgen raised projections for 2016…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
